Diseases of the Cardiovascular System, Phase III

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (ReCePI)

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on the clinical outcome of renal impairment following transfusion of red blood cells (RBCs) treated with the INTERCEPT Blood System (IBS) for Red Blood Cells compared to patients transfused with conventional RBCs.

Trial with
Cerus Corporation
Ages
11 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Kimberly Kunze

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Edward L. Snyder, MD, FACP
Professor of Laboratory Medicine; Committee Chair, Conflict of Interest; Vice Chair, DSMC Committee, Yale Cancer Center; Chair, Membership Committee, Yale Cancer Center; Director, Transfusion Service, Bridgeport/Milford; Professor, Pathology

Sub-Investigator

Chad Binns, MD

Last Updated
04/21/2023
Study HIC
#2000024812